Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). [electronic resource]
Producer: 20120712Description: 1620-7 p. digitalISSN:- 1527-7755
- Adenocarcinoma -- mortality
- Adult
- Aged
- Analysis of Variance
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Capecitabine
- Cetuximab
- Chemoradiotherapy, Adjuvant -- methods
- Colectomy -- methods
- Combined Modality Therapy
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Female
- Fluorouracil -- administration & dosage
- Follow-Up Studies
- Humans
- Intestinal Mucosa -- surgery
- Kaplan-Meier Estimate
- Logistic Models
- Male
- Middle Aged
- Neoadjuvant Therapy -- methods
- Neoplasm Invasiveness -- pathology
- Neoplasm Staging
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Preoperative Care -- methods
- Radiotherapy, Adjuvant
- Rectal Neoplasms -- mortality
- Risk Assessment
- Survival Analysis
- Treatment Outcome
- United Kingdom
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.